IRWD

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company, which is advancing the treatment of GI diseases and redefining the standard of care for GI patients. It develops and commercializes GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. LINZESS (linaclotide), its commercial product, in a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States and Mexico, IBS-C or chronic constipation in Japan, and IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.